Has Krishnendu Bhadra, MD received payments from drug or device companies?

Yes. Drug and device makers reported $494,414 in general payments to Krishnendu Bhadra, MD across 280 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Krishnendu Bhadra, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Krishnendu Bhadra, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Krishnendu Bhadra, MD

Pulmonary Disease · Chattanooga, TNNPI 1093850745

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $346,294 of the $494,414 with a category attached, or 70.0%. 22 manufacturers reported payments, led by Noah Medical Corporation at 58.6% of the total. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$494,414in general payments, 2019–2025

Across 280 payments — averaging $1765.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Noah Medical Corporation$290K
Intuitive Surgical$58K
Serpex Medical Inc$47K
Covidien LP$35K
Astrazeneca UK Limited$19K
Siemens Medical Solutions USA, Inc.$18K
plus $28K from 16 others

$137,066in research payments, 2019–2025

Across 15 payments — averaging $9137.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Siemens Medical Solutions USA, Inc.$77K
Galvanize Therapeutics, Inc$59K
Covidien LP$2K

What the payments were for

Consulting fees$346,29470%
Speaking & faculty fees$74,42015%
Travel & lodging$51,59810%
Food & beverage$14,0703%
Education$8,0312%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Noah Medical Corporation	98	$289,789
Intuitive Surgical	62	$58,276
Serpex Medical Inc	6	$46,899
Covidien LP	31	$34,889
Astrazeneca UK Limited	12	$18,877
Siemens Medical Solutions USA, Inc.	7	$17,780
Ethicon Endo-surgery Inc.	11	$6,326
Medtronic	8	$5,606
ERBE USA Inc	3	$4,539
Janssen Scientific Affairs, LLC	11	$4,450
Galvanize Therapeutics, Inc	5	$2,332
Johnson & Johnson	3	$2,256
Pulmonx Corporation	8	$1,506
Olympus America Inc.	4	$318
GE HealthCare	1	$154
Body Vision Medical Inc.	2	$147
Inari Medical, Inc.	1	$87
Insmed, Inc.	2	$51
Philips North America LLC	1	$50
4dmedical USA Inc	1	$33
Pfizer	2	$30
United Therapeutics Corporation	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$494,414 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.

See all pulmonary disease providers in Tennessee →

Medicare billing

Part B allowed, 2024

$149,622

Medicare patients

352

Services billed

2,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Chattanooga

Michael CzarneckiChattanooga$348K
Carlos BaleeiroChattanooga$265K
Vincent ViscomiChattanooga$28K
Daniel SmithChattanooga$21K
Lisa LancasterNashville$519K
Aaron MilstoneFranklin$482K
Otis RickmanNashville$392K
Susan GarwoodNashville$343K
Girendra HoskereBristol$285K
Joao DeandradeNashville$245K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →